• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Ra Medical Systems Inc. (Amendment)

    1/16/24 8:15:49 AM ET
    $RMED
    Medical/Dental Instruments
    Health Care
    Get the next $RMED alert in real time by email
    SC 13D/A 1 dsc13da.htm SC 13D/A dsc13da.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

    Catheter Precision, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 Par Value

    (Title of Class of Securities)

     

    74933X302

    (CUSIP Number)

     

    B. Joseph Alley, Jr.

    Arnall Golden Gregory LLP

    171 17th Street NW, Suite 2100

    Atlanta, GA 30363

     (404) 473-8500

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    January 10, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ☐.

     

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 74933X302

     

    Page 2 of 13

     

    1

    Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person  

     

    David Jenkins

     

     

    2

    Check the Appropriate Box if a Member of a Group

     

    (a)☒

    (b)☐

     

    3

     

    SEC Use Only

     

     

     

    4

    Source of Funds

     

    OO

     

     

    5

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

    6

    Citizenship or Place of Organization

     

    United States

     

     

    7

    Sole Voting Power

     

    277,597

     

     

    8

    Shared Voting Power

     

    714,231*

     

     

    9

    Sole Dispositive Power

     

    277,597

     

     

    10

    Shared Dispositive Power

     

    714,231*

     

     

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    991,828*

     

     

    12

    Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

     

     

    ☒

    13

    Percent of Class Represented by Amount in Row (11)

     

    14.1 percent*

     

     

    14

    Type of Reporting Person

     

    IN

     

     

    *

    Includes 2,264 shares of Company Common Stock held by the Linda Jenkins Charitable Remainder Unitrust, a charitable remainder unitrust of which Mr. Jenkins’ spouse is the trustee. Also includes 2,264 shares of Company common stock held by the Jenkins Family Charitable Institute, of which Mr. Jenkins is the sole trustee. Also includes 709,703 shares of Company Common Stock held by Fatboy Capital, L.P., a Delaware limited partnership. The general partner of Fatboy Capital, L.P.. is SeaCap Management LLC, a Wyoming limited liability company, of which Mr. Jenkins is the managing member.

     

     

     

     

    CUSIP No. 74933X302

     

    Page 3 of 13

     

    1

    Name of Reporting Person  S.S. or I.R.S. Identification No. of Above Person

     

    Fatboy Capital, L.P.

     

    2

    Check the Appropriate Box if a Member of a Group

     

     

    (a)☒

    (b)☐

    3

    SEC Use Only

     

     

     

    4

    Source of Funds

     

    OO

     

     

    5

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

    6

    Citizenship or Place of Organization

     

    Delaware

     

     

    7

    Sole Voting Power

     

    709,703

     

     

    8

    Shared Voting Power

     

    0

     

     

    9

    Sole Dispositive Power

     

    709,703

     

     

    10

    Shared Dispositive Power

     

    0

     

     

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    709,703

     

     

    12

    Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

     

    ☐

    13

    Percent of Class Represented by Amount in Row (11)

     

    10.1 percent*

     

     

    14

    Type of Reporting Person

     

    PN

     

     

     

     

     

     

    CUSIP No. 74933X302

     

    Page 4 of 13

     

    1

    Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person

     

    SeaCap Management LLC

     

    2

    Check the Appropriate Box if a Member of a Group

     

     

    (a)☒

    (b)☐

    3

    SEC Use Only

     

     

     

    4

    Source of Funds

     

    OO

     

     

    5

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

    6

    Citizenship or Place of Organization

     

    Wyoming

     

     

    7

    Sole Voting Power

     

    0

     

     

    8

    Shared Voting Power

     

    709,703*

     

     

    9

    Sole Dispositive Power

     

    0

     

     

    10

    Shared Dispositive Power

     

    709,703*

     

     

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    709,703*

     

     

    12

    Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

     

    ☐

    13

    Percent of Class Represented by Amount in Row (11)

     

    10.1 percent

     

     

    14

    Type of Reporting Person

     

    OO

     

     

       

    *

    Includes 709,703 shares of Company Common Stock held by Fatboy Capital, L.P., a Delaware limited partnership. SeaCap Management LLC is the general partner of Fatboy Capital, L.P.

     

     

     

     

    CUSIP No. 74933X302

     

    Page 5 of 13

     

    1

    Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person

     

    Linda Jenkins Charitable Remainder Unitrust

     

    2

    Check the Appropriate Box if a Member of a Group

     

     

    (a)☒

    (b)☐

    3

    SEC Use Only

     

     

     

    4

    Source of Funds

     

    OO

     

     

    5

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

    6

    Citizenship or Place of Organization

     

    Louisiana

     

     

    7

    Sole Voting Power

     

    2,264

     

     

    8

    Shared Voting Power

     

    0

     

     

    9

    Sole Dispositive Power

     

    2,264

     

     

    10

    Shared Dispositive Power

     

    0

     

     

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,264

     

     

    12

    Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

     

     

    ☐

    13

    Percent of Class Represented by Amount in Row (11)

     

    0.0 percent

     

     

    14

    Type of Reporting Person

     

    OO

     

     

     

     

     

     

    CUSIP No. 74933X302

     

    Page 6 of 13

     

    1

    Name of Reporting Person  S.S. or I.R.S. Identification No. of Above Person

     

    Jenkins Family Charitable Institute

     

    2

    Check the Appropriate Box if a Member of a Group

     

     

    (a)☒

    (b)☐

    3

    SEC Use Only

     

     

     

    4

    Source of Funds

     

    OO

     

     

    5

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

    6

    Citizenship or Place of Organization

     

    Louisiana

     

     

    7

    Sole Voting Power

     

    2,264

     

     

    8

    Shared Voting Power

     

    0

     

     

    9

    Sole Dispositive Power

     

    2,264

     

     

    10

    Shared Dispositive Power

     

    0

     

     

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,264

     

     

    12

    Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

     

    ☐

    13

    Percent of Class Represented by Amount in Row (11)

     

    0.0 percent

     

     

    14

    Type of Reporting Person

     

    OO

     

     

     

     

     

     

    CUSIP No. 74933X302

     

    Page 7 of 13

     

    1

    Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person

     

    Dalin Class Trust

     

    2

    Check the Appropriate Box if a Member of a Group

     

     

    (a)☒

    (b)☐

    3

    SEC Use Only

     

     

     

    4

    Source of Funds

     

    OO

     

     

    5

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

    6

    Citizenship or Place of Organization

     

    Louisiana

     

     

    7

    Sole Voting Power

     

    0

     

     

    8

    Shared Voting Power

     

    709,703*

     

     

    9

    Sole Dispositive Power

     

    0

     

     

    10

    Shared Dispositive Power

     

    709,703*

     

     

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    709,703*

     

     

    12

    Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

     

    ☐

    13

    Percent of Class Represented by Amount in Row (11)

     

    10.1 percent

     

     

    14

    Type of Reporting Person

     

    OO

     

     

     

     

    *

    Includes 709,703 shares of Company Common Stock held by Fatboy Capital, L.P., a Delaware limited partnership. Dalin Class Trust is a general partner of Fatboy Capital, L.P.

     

     

     

     

    CUSIP No. 74933X302

     

    Page 8 of 13

     

    Item 1. Security and Issuer

     

    This Amendment No. 1 to Schedule 13D relates to the common stock, $0.0001 par value per share (the “Common Stock”), of Catheter Precision, Inc., a Delaware corporation (the “Company”). The original Schedule 13D was filed on March 29, 2023. (the “Initial Schedule 13D”). The Initial Schedule 13D is incorporated by reference herein. The principal executive office of the Company is located at:

     

    1670 Highway 160 West

    Suite 205

    Fort Mill, SC 29708

     

    Item 2. Identity and Background

     

     

    1.

    (a)

    David Jenkins is a reporting person filing this statement.

     

     

     

     

     

     

    (b)

    c/o of Catheter Precision, Inc., 1670 Highway 160 West, Suite 205, Fort Mill, SC 29708.

     

     

     

     

    (c)

    Executive Chairman of the Board and Chief Executive Officer of the Company, engaged in the design, manufacture and sale of new and innovative medical technologies focused in the field of cardiac electrophysiology, the business address of which is 1670 Highway 160 West, Suite 205, Fort Mill, SC 29708.

     

     

     

     

     

     

    (d)

    None.

     

     

     

     

     

     

    (e)

    None.

     

     

     

     

     

     

    (f)

    United States.

    .

     

     

      

    CUSIP No. 74933X302

     

    Page 9 of 13

     

     

    2.

    Fatboy Capital, L.P. is a reporting person filing this statement. It is a Delaware limited partnership, and its principal business address is 9611 North US Hwy 1, Box 390, Sebastian FL 32958. Its principal business is to serve as a private investment holding company

     

     

     

     

     

     

    (d)

    None.

     

     

     

     

     

     

    (e)

    None.

     

     

     

     

     

    3.

    The Jenkins Family Charitable Institute is a reporting person filing this statement. It is a private foundation, and its principal business address is 9611 North US Hwy 1, Box 390, Sebastian FL 32958. Its principal business is to serve as a family charitable entity.

     

     

     

     

     

     

    (d)

    None.

     

     

     

     

     

     

    (e)

    None.

     

     

     

     

     

    4.

    The Linda Jenkins Charitable Remainder Unitrust is a reporting person filing this statement.  It is a Louisiana charitable remainder unitrust, and its principal business address is PO Box 682838, Park City UT 84068-2838.  Its principal business is to serve as a charitable trust and to facility estate planning.

     

     

     

     

     

     

    (d)

    None.

     

     

     

     

     

     

    (e)

    None.

     

     

     

     

     

    5.

    SeaCap Management LLC is a reporting person filing this statement. It is a Wyoming limited liability company, and its principal business address is 9611 North US Hwy 1, Box 390, Sebastian FL 32958. Its principal business is to serve as a family investment manager.

     

     

     

     

     

     

    (d)

    None.

     

     

     

     

     

     

    (e)

    None.

     

     

     

     

     

    6.

    (a)

    Linda Jenkins is a the trustee of the Linda Jenkins Charitable Remainder Unitrust, which is a reporting person filing this statement.

     

     

     

     

     

     

    (b)

    PO Box 682838, Park City UT 84068-2838.

     

     

     

     

     

     

    (c)

    Retired.

     

     

     

     

     

     

    (d)

    None.

     

     

     

     

     

     

    (e)

    None.

     

     

     

     

     

     

    (f)

    United States.

     

     

     

     

     

    7.

    Dalin Class Trust is a person filing this statement. David Jenkins is the sole trustee of Dalin Class Trust. Its principal business address is 9611 North US Hwy 1, Box 390, Sebastian FL 32958. It is a family trust.

     

     

     

     

     

    (d)

    None.

     

     

     

     

     

     

    (e)

    None.

     

     

     

     

    CUSIP No. 74933X302

     

    Page 10 of 13

     

    Item 3. Source and Amount of Funds or Other Consideration

     

    See the Initial Schedule 13D for historical information.

     

    Item 4 below is incorporated by reference herein.  The source of funds for all proposed purchases described in Item 4 below is cash on hand or working capital.  The amount of funds used will depend on the trading price and volume of Company common stock and the amount of shares ultimately purchased.  None of the funds used to make any purchases are or will be represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting Company common stock.

     

    Item 4. Purpose of Transaction

     

    See the Initial Schedule 13D for historical information.

     

    On January 11, 2024, the Company announced that its Board of Directors has authorized Mr. David Jenkins and his affiliated companies to purchase up to 500,000 shares of Company common stock on the open market.  Although it is Mr. Jenkins’ current intent to engage in open market purchase transactions from time to time, his decision as to whether to engage in a purchase at any given time will depend upon a number of factors, including the current trading price of Company common stock and Mr. Jenkins’ other capital needs.  Mr. Jenkins also reserves the right to make purchases in private transactions.  There is no guarantee that all or a substantial portion of the shares authorized as described above will in fact be purchased, and Mr. Jenkins reserves the right to make private purchases or purchases directly from the Company, subject to compliance with rules of the NYSE American.   All purchases by Mr. Jenkins and affiliated companies will be made in compliance with all applicable laws, and all open market transactions will be conducted pursuant to Rule 10b-18 under the Securities Exchange Act of 1934, as amended.   

     

    All acquisitions described above are expected to be for investment purposes.  The reporting persons and other persons listed in Item 2 may make additional open market or other purchases or sales or engage in estate planning or other transactions in Company common stock, from time to time.  

     

    Except as noted above and below in this Item 4, the reporting persons and the other persons listed in Item 2 have no present intent to take any action that would result in:

     

    (a) the acquisition by any person of additional securities of the Company or the disposition of securities of the Company;

     

    (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any subsidiary thereof;

     

    (c) a sale or transfer of a material amount of assets of the Company or any subsidiary thereof;

     

    (d) any change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

     

    (e) any material change in the present capitalization or dividend policy of the Company;

     

    (f) any other material change in the Company’s business or corporate structure;

     

    (g) any changes in the Company’s charter, bylaws, or instruments corresponding thereto, or other actions which may impede the acquisition of control of the Company by any person;

     

     

     

     

    CUSIP No. 74933X302

     

    Page 11 of 13

     

    (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

     

    (i) a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or

     

    (j) any action similar to any of those enumerated above.

     

    Notwithstanding the foregoing, Mr. Jenkins exercises control over the Company to the extent that he is a director and executive officer of the Company, and may consider various transactions that are in the best interests of the Company from time to time, including transactions of the types described above, and the reporting persons and the other persons listed in Item 2 will continue to review their investment in the Company, and reserve the right to change their intentions with respect to any or all of such matters.

     

    Item 5. Interest in Securities of the Issuer

     

    See the Initial Schedule 13D for historical information.                            

     

    (a)-(b)

    See the cover pages to this Amendment.

     

    Ms. Linda Jenkins beneficially owns 2,264 shares of Company common stock as a result of her position as the sole trustee of the Linda Jenkins Charitable Remainder Trust.

     

     

     

    (c)

    There were no transactions in Company common stock effected by the reporting persons or the other persons listed in Item 2 within 60 days of the date hereof. See the Initial Schedule 13D for historical information.

     

     

     

     

     

     

    (d)

    None.

     

     

     

     

     

     

    (e)

    Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    See the Initial Schedule 13D for historical information. Mr. Jenkins has agreed with the Company that all purchases described in Item 4 above will be made in compliance with all applicable laws, and that any such open market purchases will be made in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended.

     

    Item 7. Material to be Filed as Exhibits

     

    (A) Agreement of filing persons relating to filing of joint statement per Rule 13d-1(k).

     

    See the Initial Schedule 13D for historical information.

     

     

     

     

    CUSIP No. 74933X302

     

    Page 12 of 13

     

    Signature.

     

    After reasonable inquiry each of the undersigned certifies that to the best of his or her knowledge and belief the information set forth in this statement is true, complete and correct.

     

    /s/ David Jenkins 

     

    Date: January 10, 2023

    DAVID JENKINS 

     

     

     

     

     

     

    FATBOY CAPITAL, L.P.

     

     

     

     

     

    By: 

    SEACAP MANAGEMENT LLC, General Partner

     

     

     

     

     

     

    By:

    /s/ David Jenkins

     

    Date: January 10, 2023

     

    David Jenkins, Managing Member

     

     

     

     

     

     

    SEACAP MANAGEMENT LLC

     

     

     

     

     

     

    By:

    /s/ David Jenkins

     

     Date: January 10, 2023

     

    David Jenkins, Managing Member

     

     

     

     

     

     

    LINDA JENKINS CHARITABLE REMAINDER UNITRUST

     

     

     

     

     

     

    By:

    /s/ Linda Jenkins

     

     Date: January 10, 2023

     

    Linda Jenkins, Trustee

     

     

     

     

     

     

    JENKINS FAMILY CHARITABLE INSTITUTE

     

     

     

     

     

     

    By:

    /s/ David Jenkins

     

     Date: January 10, 2023

     

    David Jenkins, Trustee

     

     

     

     

     

     

    DALIN CLASS TRUST

     

     

     

     

     

     

    By:

    /s/ David Jenkins

     

    Date: January 10, 2023

     

    David Jenkins, Trustee

     

     

     

     

     

     

    EXHIBIT A

     

    The undersigned each hereby certifies and agrees that the above Amendment to Schedule 13D concerning securities issued by Catheter Precision, Inc. is being filed on behalf of each of the undersigned.

     

    /s/ David Jenkins 

     

    Date: January 10, 2023

    DAVID JENKINS 

     

     

     

     

     

     

    FATBOY CAPITAL, L.P.

     

     

     

     

     

    By: 

    SEACAP MANAGEMENT LLC, General Partner

     

     

     

     

     

     

    By:

    /s/ David Jenkins

     

    Date: January 10, 2023

     

    David Jenkins, Managing Member

     

     

     

     

     

     

    SEACAP MANAGEMENT LLC

     

     

     

     

     

     

    By:

    /s/ David Jenkins

     

     Date: January 10, 2023

     

    David Jenkins, Managing Member

     

     

     

     

     

     

    LINDA JENKINS CHARITABLE REMAINDER UNITRUST

     

     

     

     

     

     

    By:

    /s/ Linda Jenkins

     

     Date: January 10, 2023

     

    Linda Jenkins, Trustee

     

     

     

     

     

     

    JENKINS FAMILY CHARITABLE INSTITUTE

     

     

     

     

     

     

    By:

    /s/ David Jenkins

     

     Date: January 10, 2023

     

    David Jenkins, Trustee

     

     

     

     

     

     

    DALIN CLASS TRUST

     

     

     

     

     

     

    By:

    /s/ David Jenkins

     

    Date: January 10, 2023

     

    David Jenkins, Trustee

     

     

      

     

     

    Get the next $RMED alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RMED

    DatePrice TargetRatingAnalyst
    10/21/2021$12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Ra Medical Systems with a new price target

      HC Wainwright & Co. initiated coverage of Ra Medical Systems with a rating of Buy and set a new price target of $12.00

      10/21/21 6:17:16 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems downgraded by Maxim Group

      Maxim Group downgraded Ra Medical Systems from Buy to Hold

      3/17/21 8:31:51 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    SEC Filings

    See more
    • Ra Medical Systems Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

      8-K - Catheter Precision, Inc. (0001716621) (Filer)

      1/25/24 4:15:50 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Catheter Precision, Inc. (0001716621) (Filer)

      1/11/24 4:15:46 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Inc. filed SEC Form 8-K: Leadership Update

      8-K - Catheter Precision, Inc. (0001716621) (Filer)

      1/4/24 4:20:59 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jenkins David A bought $9,786 worth of shares (19,056 units at $0.51), increasing direct ownership by 6% to 329,856 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/24/24 4:15:18 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Jenkins David A bought $7,086 worth of shares (16,940 units at $0.42), increasing direct ownership by 6% to 310,800 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/22/24 4:15:35 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Jenkins David A bought $6,323 worth of shares (16,263 units at $0.39), increasing direct ownership by 6% to 293,860 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/18/24 4:15:33 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ra Medical Systems Inc.

      SC 13G - Catheter Precision, Inc. (0001716621) (Subject)

      2/14/24 3:57:22 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Ra Medical Systems Inc. (Amendment)

      SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

      1/16/24 8:15:49 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Ra Medical Systems Inc.

      SC 13G - Ra Medical Systems, Inc. (0001716621) (Subject)

      3/31/23 4:15:34 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jenkins David A bought $9,786 worth of shares (19,056 units at $0.51), increasing direct ownership by 6% to 329,856 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/24/24 4:15:18 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Jenkins David A bought $7,086 worth of shares (16,940 units at $0.42), increasing direct ownership by 6% to 310,800 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/22/24 4:15:35 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Jenkins David A bought $6,323 worth of shares (16,263 units at $0.39), increasing direct ownership by 6% to 293,860 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/18/24 4:15:33 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Reminder: Ra Medical Systems Announces Name and Ticker Symbol Changes

      Name change to Catheter Precision, Inc. is effective on August 17, 2023, with trading under new ticker symbol VTAK to begin on August 18, 2023FORT MILL, SC / ACCESSWIRE / August 17, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced that its Board of Directors has approved changing the Company's corporate name to "Catheter Precision, Inc." The effective date of the name change is today, August 17, 2023. The Company has reserved the ticker symbol "VTAK" with the NYSE American, and the Company's common stock is expected to begin trading on the NYSE American under its new name and the new trading symbol effective as of the market open on August 18, 2023. The Company's new website will be unv

      8/17/23 8:00:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Announces Allowance of New Closure Device Patent

      First patent out of six applications on file for LockeT productFORT MILL, SC / ACCESSWIRE / August 14, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced that it has received notification of allowance of the first patent to be issued for the company's LockeT product. Entitled "Vessel Closing Device", the patent to be granted is one in a family of six patent applications on file in the US, and in a number of foreign countries, including the European Community, Japan, and China.David Jenkins, interim CEO of Ra Medical Systems, commented, "We are pleased to see the first of what should be several patents to come about with the LockeT closure device. It is a clever design and invention,

      8/14/23 8:00:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Announces Milestone Achievement for Electrophysiology Division

      Catheter Precision's VIVO System Has Been Utilized in over 1,000 ProceduresFORT MILL, SC / ACCESSWIRE / August 7, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced today that VIVO, the lead product for the electrophysiology division, has been used in more than 1000 ventricular ablation procedures. VIVO, which stands for View Into Ventricular Onset, enables physicians to learn more about patient specific anatomy and better help them plan the ablation procedure. As a result, VIVO aids in reducing overall procedure time benefitting physicians, hospitals and patients."I made a conscious decision to support a pre-commercial roll out with my own capital. I've invested well over $25mm at an ave

      8/7/23 8:00:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Leadership Updates

    Live Leadership Updates

    See more
    • Ra Medical Systems Announces First Quarter Results

      FORT MILL, SC / ACCESSWIRE / June 2, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced financial and company highlights for the first quarter ended March 31,2023. Among the quarter highlights are the following:RMED concluded the acquisition with the private, company Catheter Precision, Inc. ("Catheter"), in January 2023. Catheter is in the MedTech space of cardiac electrophysiology.Catheter onboarded five direct salespersons and several field clinical persons to assist in the broad US launch of its VIVO product, a product utilized to non-invasively determine the source, or earliest activation, of a ventricular arrhythmia.Catheter introduced to the market its new LockeT closure devi

      6/2/23 6:35:00 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Announces Resignation of CEO

      Board Committee Seeking ReplacementFORT MILL, SC / ACCESSWIRE / April 18, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced today the resignation of its CEO, Will McGuire, for personal reasons. The resignation will be effective April 28, 2023. In conjunction with his resignation as CEO, Mr. McGuire is also resigning from the RMED board of directors. The Company thanks Mr. McGuire for his service and contributions and wishes him the best in future endeavors.The RMED board of directors, as part of its governance commitment, last month established a committee for examining a transition at the CEO level. Mr. David Jenkins, the Company's Executive Chairman of the Board, will serve as Interim

      4/18/23 8:00:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Announces Change in Chief Financial Officer Position Previous Acting CFO Position Replaced with Permanent Appointment

      FORT MILL, SC / ACCESSWIRE / March 30, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced the appointment of Steven Passey as Chief Financial Officer effective April 1, 2023, replacing Brian Conn, who has been serving as Acting Chief Financial Officer."Steven joins the executive team at a pivotal time in Ra Medical's growth", stated Ra Medical's Executive Chairman of the Board David Jenkins. "His background with publicly traded companies, budget and cost control ensures we will maintain the highest standards as a public company. In addition, he is a seasoned executive who has led M&A transactions as well as numerous equity and debt financing transactions for strategic growth. His ex

      3/30/23 7:30:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Financials

    Live finance-specific insights

    See more
    • Ra Medical Systems Announces Date of Special Shareholder Meeting

      FORT MILL, SC / ACCESSWIRE / February 10, 2023 / Ra Medical Systems (NYSE:RMED) today announced the date of March 21, 2023 as the date of its special shareholder meeting. Shareholders of record as of February 3, 2023 are entitled to vote at the meeting.Among other items, shareholders are requested to vote in favor of a previously announced $8 million private financing, and to vote in favor of the conversion of RMED preferred stock into common stock, the majority of which will not be converted until mid-2024, at the earliest. The preferred stock was issued in connection with the acquisition of Catheter Precision, Inc., earlier this year.About Ra Medical SystemsRa Medical, and its wholly owned

      2/10/23 9:20:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems to Report First Quarter 2022 Financial Results on May 16, 2022

      Ra Medical Systems, Inc. (NYSE:RMED) announces that it will report financial results for the three months ended March 31, 2022 after market close on Monday, May 16. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update. Pre-Registration   Participants can pre-register for the conference call here:           Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

      5/9/22 6:50:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Reports 2021 Fourth Quarter and Full Year Financial Results

      Conference call begins at 4:30 p.m. Eastern time today Ra Medical Systems, Inc. (NYSE:RMED), a medical device company focusing on developing its excimer laser system to treat vascular disease, reports financial results for the three months and full year ended December 31, 2021 and provides a business update. Recent Operational Highlights Filed 510(k) application with the FDA for our next-generation DABRA catheter that incorporates a braided overjacket designed to improve robustness and includes data supporting a six-month shelf life Enrolled 13 subjects in the company's atherectomy pivotal clinical study since mid-November 2021, for a total of 98 subjects enrolled, and received approv

      3/23/22 4:05:00 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care